GEN Exclusives

More »

GEN News Highlights

More »
Oct 18, 2007

Cobra to Continue Backing Advaxis’ Cervical Cancer Vaccine Clinical Trials

  • Cobra Biomanufacturing will produce material for use in Advaxis’ Phase II trial of its cervical cancer vaccine, Lovaxin C. Cobra has been supporting the Advaxis Lovaxin C clinical program since 2003, according to David Thatcher, CEO of Cobra.

    “We look forward to continuing our relationship with Cobra as we move forward with the development of live Listeria vaccines for the treatment of cancer,” says John Rothman, vp, clinical development. “Our initial clinical work demonstrated the real-world utility of our concepts, and Cobra’s ability to execute their production as potential cancer immunotherapeutic agents.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?